Form 4: Allogene Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Zachary Roberts, EVP of R&D at Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On February 3, 2025, Zachary Roberts, the EVP of R&D at Allogene Therapeutics, sold 18,832 shares of common stock at a price of $1.7 per share.
- The sale was mandated by Allogene Therapeutics' equity incentive plan to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Roberts directly owns 643,135 shares of Allogene Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't provide strong positive or negative signals about the company's prospects.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction is not necessarily indicative of the executive's sentiment towards the company's future prospects.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, although it is a common practice for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of the transaction (sale of shares). |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.